Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

Ṁ1kṀ2.7k

2028

86%

chance

ALL

Will have to adjust resolve date based on when CDC releases the data. If the rate decreases while all the products are pulled from market, or not sold in a reasonable quantity, it won't count.

Market context

Science

Health

Medicine

Get

1,000

to start trading!

People are also trading

Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025

71% chance

Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?

30% chance

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

10% chance

What fraction of US adults will regularly take GLP-1 drugs in 2030?

Will a majority government owned company introduce a new GLP-1 drug before 2040?

15% chance

Will US obesity decrease by more than 1% before 2030?

85% chance

Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?

45% chance

Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss

55% chance

By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?

86% chance

Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?

Sort by:

https://x.com/EricTopol/status/1988281258007556136

bmi went down in 2023

"Help stop" is just . . . the rate goes down at all and we attribute it to GLP-1 agonists? This seems poorly defined.

I assume this resolves positively based entirely on obesity rates in the US, is that correct? I guess if GLP-1 Agonists are entirely pulled from the market it will resolve negatively regardless of obesity rates?